Infrareal holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.

Global leader in R&D sample stability and biorepository storage Astoriom has announced the acquisition of both MTS Cryo stores and Cool Repair Scientific UK (both Nottingham, UK).

Earlier this year, Axol Bioscience announced the acquisition of Phenocell SAS with the goal of expanding cell models and services to include dermatology and ophthalmology.

The CDMO launched earlier this year at the CPHI conference in Milan, Italy.

Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (kmo) inhibitors – has been acquired by Dr. Falk Pharma.

Merck and EyeBiotech Limited, have announced that the two companies have entered into a definitive agreement under which Merck, through one of its subsidiaries, will acquire EyeBio.

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon.

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global compounding operator as well as to allow icon to enter the UK market.

Biogen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire HI-Bio for $1.15bn upfront, alongside up to $650m in potential milestone payments.

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos for an approximate $137.5m ‒ or $20.42 per share ‒ adding to its portfolio in inflammatory and autoimmune diseases.

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, totalling an approximate $4.9bn.